Introduction
Invasive fungal infections pose a serious threat to patients being treated for acute leukemia and to recipients of hematopoietic stem cell transplants. Among the emerging pathogens, Saprochaete capitata (formerly known as Geotrichum capitatum and Blastoschizomyces capitatus ) is a rarely described mould that produces severe systemic infection in such patients [1, 2] which are commonly reported as breakthrough events [1, 3] . Although the optimal antifungal therapy for these infections remains somewhat unclear, it appears that echinocandins are ineffective [4] . We hereby report the case of a S. capitata breakthrough infection occurring in a patient with acute myeloid leukemia receiving empirical caspofungin therapy for neutropenic fevers. In addition, we consecutively review all cases of breakthrough infections due to this fungus in patients receiving empirical echinocandin therapy. treatment consisting of cytarabin and amsacrin was started but due to relapsing fever, ceftazidim and teicoplanin were stopped on day 27 and meropenem was started with the continuation of the caspofungin therapy. The blood cultures taken on day 34, 35 and 36 yielded a yeast-like fungus. Those taken on day 35 and 36 were drawn through a central venous catheter. On day 36, the patient developed an acute abdomen which led to a CT scan that revealed two large hypodense zones in the liver. Fine needle aspirate of the lesions showed a minimal amount of pus, but Gram staining of a portion of this material did not show any micro-organisms or fungal structures. A few hours later, the patient developed an abdominal compartment syndrome requiring intubation and ventilation. Despite aggressive supportive therapy, the patient ' s condition deteriorated and she died the next day. The central venous catheter had not been removed.
Meanwhile, the yeast-like fungus detected in the blood cultures was identifi ed as S. capitata . Colonies on blood agar were white to cream-colored, while those on corn meal agar showed ' bamboo-like ' conidiophores with elongated conidia fl attened at the base suggesting S. capitata (teleomorph Magnusiomyces capitatus ) ( Fig. 1 ). Arthroconidia were evident on Sabouraud dextrose agar cultures (Fig. 2 ). Negative urease test results excluded Trichosporon spp. and the assimilation pattern found with the API ID 32 C (BioM é rieux, Brussels, Belgium) confi rmed the identifi cation of Geotrichum capitatum (3210010001, %ID 99.6). In vitro susceptibility testing against fl uconazole, voriconazole, amphotericin B, anidulafungin and caspofungin was performed using Sensititre ® YeastOne (TREK Diagnostic System, East Grinstead, UK). Minimal inhibitory concentrations for amphotericin B, anidulafungin, caspofungin, fl uconazole and voriconazole were 1 mg/l, 2 mg/l, Ͼ 8 mg/l, 32 mg/l, and 1 mg/l, respectively.
Discussion
Geotrichum capitatum , formerly known as Trichosporon capitatum and Blastoschizomyces capitatus (teleomorph Dipodascus capitatus ) has undergone extensive taxonomic evaluation [5] . In light of its cell wall structure and septal pores, as well as its tendency to produce numerous arthroconidia and few blastoconidia, it was included among the Ascomycete s [2] . A recent revision of the 32 taxa of the fi lamentous Hemiascomycetes suggested, based on the ribosomal structure, that this class could be divided into a Group 1 which includes Geotrichum anamorph consisting of Galactomyces and Dipodascus teleomorph and a Group 2 consisting of Saprochaete anamorph with Magnusiomyces teleomorph. According to this new taxonomic proposal, Geotrichum capitatum was re-named S. capitata (teleomorph Magnusiomyces capitatus ) [5] .
S. capitata is an emerging cause of invasive and disseminated infections, especially in immune compromised haematological patients, although solid tumour-associated pathologies and onychomycosis in immunocompetent hosts have also been reported [6] . In the past 4 years, there have been four reports of breakthrough infections caused by S. capitata in patients receiving empirical echinocandin therapy [4, 7, 8] (Table 1) . Risk factors for systemic infections in these patients were prolonged neutropenia, aggressive chemotherapy, the use of broad spectrum antibiotics and the alteration of local defenses by breakdown of skin and mucosa [9] . The most common underlying haematological malignancy in patients with invasive infections is acute myeloid leukemia and the incidence rate among patients with acute leukemia is estimated to be around 0.5% [2, 10] . Indeed, all of the described cases of breakthrough infections were in patients with acute leukemia (one acute lymphoblastic leukemia and four acute myelogenous leukemia) who received intensive chemotherapy. Furthermore, all patients received broad spectrum antibiotics because of neutropenic fever. The 30 day mortality associated with invasive disease ranges from 60 -80% [2], but in the case series we describe, mortality was 100%.
The clinical features of invasive infection with S. capitata frequently resemble those of invasive candidiosis, with the exception that those with disseminated S. capitata infection frequently show microbiologically documented invasive tissue localization [11] . A brain abscess was demonstrated in only 1/5 patients with a breakthrough infection with invasive tissue localization. In our patient, the development of liver abscesses could have been a sign of tissue invasion by S. capitata , although cultures of the evacuated pus remained negative. Furthermore, candidemia is more frequently related to the presence of a central venous catheter than invasive S. capitata infection [11] . In our case series only one patient had proven central venous catheter infection. Our own patient probably had central venous catheter infection, although the catheter was not removed and cultured to prove infection.
Blood cultures, which are the standard for diagnosing S. capitata infections, are negative in about 30% of cases and usually take several days to show detectable growth [7] . S. capitata is known to have galactomannan as a cell wall component, which can be detected by using the Aspergillus galactomannan assay [7, 8] . Knowledge of this phenomenon may be useful in the diagnosis and management of S. capitata infections. However, the detection of galactomannan antigen cannot be considered as a specifi c diagnostic marker of S. capitata deep infections because positive results due to Aspergillus spp. is much more likely in this patient population. Positive Aspergillus galactomannan assays were noted with three patients with breakthrough infections due to S. capitata . In our patient, Aspergillus galactomannan assays were repeatedly negative and the diagnosis could only be made due to the growth of the microorganism in the blood cultures.
Fungal infections are reported in 14% of the patients undergoing chemotherapy for acute leukemia [12] . The main risk group for which empirical caspofungin therapy might prove useful are patients with acute leukemia and prolonged neutropenia ( Ͻ 500 cells per mm 3 for more than 10 days) or allogeneic stem cell transplantation [13] . In a recent paper, the incidence of breakthrough invasive fungal disease was reported to be 10.7% in patients treated empirically with caspofungin and 12.1% in patients treated empirically with micafungin [14] . In 2004, Walsh et al . described breakthrough infections in 5.2% of the patients treated empirically with caspofungin [15] . However, in neither of the two studies were breakthrough infections caused by S. capitata . In the past 4 years, there have been four cases of breakthrough infections due to this mould and our patient represents the fi fth such case [4, 7, 8] . We instituted empirical caspofungin treatment when fever persisted despite administration of broad spectrum antibiotic coverage. Because of repeated negative results with the Aspergillus galactomannan assay, treatment with caspofungin was empirically continued and not switched to voriconazole or posaconazole. Blood cultures eventually yielded an isolate of S. capitata which was found to be resistant to caspofungin, but by that time our patient had died. In the other four reported cases, therapy was switched to voriconazole, with or without amphotericin B, but none of the patients survived.
In vitro susceptibilities determined by the clinical laboratory standards institute (CLSI) methods indicate that S. capitata is highly susceptible to amphotericin B, itraconazole and voriconazole. Although most isolates were susceptible to fl ucytosine and fl uconazole, strains have been observed with decreased susceptibilities to both agents [16, 17] . Data on the in vitro susceptibility of S. capitata to echinocandins are summarized in Table 2 [6,7,18 -20] . While limited, the results suggest that echinocandins seem to lack activity against this fungus [16, 17] . However, despite Franchi et al . ' s reported successful treatment of S. capitata pneumonia in a leukemia patient with voriconazole and caspofungin, the correlation between in vitro test results and treatment outcomes for echinocandins in invasive S. capitata infection has not been fully established [20] . Chittick et al . reported a breakthrough infection caused by an isolate of S. capitata which showed in vitro susceptibility to micafungin in a patient who received micafungin [4, 20] . Because in vitro susceptibility data are limited, a careful evaluation of each S. capitata isolate is needed. Our isolate showed susceptibility to amphotericin B and voriconazole and resistance to caspofungin which is in accordance with the known in vitro results [16, 17] . The optimal antifungal therapy for S. capitata remains somewhat unclear. Although published clinical data are limited, in vitro data provide encouraging evidence of the potential role of voriconazole in the treatment of S. capitata infections [2].
In conclusion, our case shows that clinicians should be aware of a possible S. capitata infection in neutropenic patients, especially those with acute myeloid leukemia treated with chemotherapy who remain febrile despite 
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